Form 4: Ligand Pharmaceuticals CEO Todd Davis Increases Stake in Company

Ligand Pharmaceuticals' CEO, Todd C. Davis, recently acquired additional shares of the company's common stock through a series of transactions.

Summary

• On May 9, 2025, Todd C. Davis, the CEO of Ligand Pharmaceuticals, purchased shares of LGND common stock in multiple transactions.
• He acquired 1,680 shares at a price of $104.57 per share, 2,307 shares at a weighted average price of $104.5295, and 5,523 shares at a weighted average price of $105.6725.
• Following these transactions, Davis directly owns 161,234 shares of Ligand Pharmaceuticals.
• The purchases were executed under SEC Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's just an insider purchase, it can signal confidence. However, it's a routine filing.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. It's a common practice and is closely monitored by investors.

Stakeholder Impact

• The CEO's increased stake could positively influence shareholder sentiment.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Todd C. Davis, insider trading, stock purchase, Form 4, CEO, ownership